| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | — | — | — | — | — | — |
| 3d | — | — | — | — | — | — |
| 1w | — | — | — | — | — | — |
| 1m | — | — | — | — | — | — |
| 3m | — | — | — | — | — | — |
| 6m | — | — | — | — | — | — |
| 1y | — | — | — | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
Cigna trades at ~9.2x forward P/E with $279/share valuation, supported by strong Q2 revenue growth (+7% YoY), $9.6B operating cash flow, and $6.5B buyback authorization. A conservative DCF model suggests intrinsic value around $390/share, implying substantial margin of safety despite regulatory headwinds priced into the low multiple.
Cigna trades at a 9.2x forward P/E on 2026 EPS guidance of $30.45, appearing deeply discounted relative to conservative DCF valuation around $390/share. While PBM regulation poses genuine risk, the company's strong cash generation, 7% revenue growth, and aggressive buybacks suggest significant upside if regulatory concerns ease.
End of results.